NeuroSense wins South Korean patent for PrimeC ALS drug composition through 2042

NeuroSense

NeuroSense

NRSN

0.00
  • NeuroSense Therapeutics received a South Korean patent covering PrimeC’s composition for amyotrophic lateral sclerosis, including formulation, manufacturing, and use claims.
  • The patent runs through 2042 in South Korea, strengthening IP protection as the company moves toward Phase 3 development.
  • The company has FDA clearance to start its pivotal Phase 3 PARAGON study, following Phase 2b data it described as supporting efficacy and survival.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Neurosense Therapeutics Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-067577), on June 11, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.